<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Iwanaka T</submitter><funding>KAKENHI</funding><funding>KAKENI</funding><pagination>134</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7093986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Human deciduous pulp stem cells (hDPSCs) have remarkable stem cell potency associated with cell proliferation, mesenchymal multipotency, and immunosuppressive function and have shown beneficial effects in a variety of animal disease models. Recent studies demonstrated that hDPSCs exhibited in vivo anti-fibrotic and anti-inflammatory action and in vivo hepatogenic-associated liver regeneration, suggesting that hDPSCs may offer a promising source with great clinical demand for treating liver diseases. However, how to manufacture ex vivo large-scale clinical-grade hDPSCs with the appropriate quality, safety, and preclinical efficacy assurances remains unclear.&lt;h4>Methods&lt;/h4>We isolated hDPSCs from human deciduous dental pulp tissues formed by the colony-forming unit-fibrob</pubmed_abstract><journal>Stem cell research &amp; therapy</journal><pubmed_title>A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment.</pubmed_title><pmcid>PMC7093986</pmcid><funding_grant_id>25293405</funding_grant_id><funding_grant_id>17K11513</funding_grant_id><funding_grant_id>18K08598</funding_grant_id><funding_grant_id>16H02682</funding_grant_id><pubmed_authors>Matsuura T</pubmed_authors><pubmed_authors>Yamaza T</pubmed_authors><pubmed_authors>Sonoda S</pubmed_authors><pubmed_authors>Iwanaka T</pubmed_authors><pubmed_authors>Yoshimaru K</pubmed_authors><pubmed_authors>Oda Y</pubmed_authors><pubmed_authors>Yamaza H</pubmed_authors><pubmed_authors>Ohga S</pubmed_authors><pubmed_authors>Taguchi T</pubmed_authors></additional><is_claimable>false</is_claimable><name>A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment.</name><description>&lt;h4>Background&lt;/h4>Human deciduous pulp stem cells (hDPSCs) have remarkable stem cell potency associated with cell proliferation, mesenchymal multipotency, and immunosuppressive function and have shown beneficial effects in a variety of animal disease models. Recent studies demonstrated that hDPSCs exhibited in vivo anti-fibrotic and anti-inflammatory action and in vivo hepatogenic-associated liver regeneration, suggesting that hDPSCs may offer a promising source with great clinical demand for treating liver diseases. However, how to manufacture ex vivo large-scale clinical-grade hDPSCs with the appropriate quality, safety, and preclinical efficacy assurances remains unclear.&lt;h4>Methods&lt;/h4>We isolated hDPSCs from human deciduous dental pulp tissues formed by the colony-forming unit-fibrob</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Mar</publication><modification>2025-04-18T11:51:18.572Z</modification><creation>2020-05-22T14:37:04Z</creation></dates><accession>S-EPMC7093986</accession><cross_references><pubmed>32213198</pubmed><doi>10.1186/s13287-020-01630-w</doi></cross_references></HashMap>